(i) mRNA vaccines. In one such preclinical study, Kreiter et al. used three independent murine tumor models and show that the majority of the non-synonymous tumor mutations are recognized by CD4+ T cells and vaccination with such CD4+ immunogenic mutations induce potent anti-tumor responses [100]. Here, CD4 is linked to neoplasm.